These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 37345111)

  • 1. Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints.
    Dulal D; Boring A; Terrero D; Johnson T; Tiwari AK; Raman D
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
    Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
    Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
    Shen M; Jiang K; Sui Y; Xu Z; Cui H; Wang Y; Zhang H; Xu Z; Xu W; Ding Q; Chen Y
    Lung Cancer; 2021 Oct; 160():84-91. PubMed ID: 34479175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
    Sasidharan Nair V; Toor SM; Taha RZ; Shaath H; Elkord E
    Clin Epigenetics; 2018 Aug; 10(1):104. PubMed ID: 30081950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
    Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
    Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
    Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
    Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients.
    Elashi AA; Sasidharan Nair V; Taha RZ; Shaath H; Elkord E
    Oncoimmunology; 2019; 8(2):e1542918. PubMed ID: 30713804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
    Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
    Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
    Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of immune checkpoints in T cells of esophageal cancer patients.
    Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
    Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients.
    Al-Mterin MA; Alsalman A; Elkord E
    Front Immunol; 2022; 13():870283. PubMed ID: 35432324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection.
    Sun Y; Xue J
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma.
    Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Lea J; Panwar V; Zheng W; Castrillon DH; Lucas E
    Mod Pathol; 2024 Aug; 37(8):100532. PubMed ID: 38848896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
    Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
    Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging immune checkpoints for cancer therapy.
    Li X; Hu W; Zheng X; Zhang C; Du P; Zheng Z; Yang Y; Wu J; Ji M; Jiang J; Wu C
    Acta Oncol; 2015 Nov; 54(10):1706-13. PubMed ID: 26361073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.